

<b>Contents of Supporting Information</b>	<b>Page #</b>
<b>Contents</b>	S1–S2
<b>I. General Experimental Protocols</b>	S3
<b>II. Procedures for preparation of and characterization data for each new isolated compound</b>	S4–S22
<b>General Procedures A, B, and C</b>	S4
<b>11</b>	S5
<b>12a</b>	S6
<b>SI-1</b>	S7
<b>12b</b>	S8
<b>SI-2</b>	S9
<b>12c</b>	S10
<b>SI-3</b>	S11
<b>12d</b>	S12
<b>SI-4</b>	S13
<b>12e</b>	S14
<b>SI-5</b>	S15
<b>12f</b>	S16
<b>SI-6</b>	S17
<b>12g</b>	S18
<b>SI-7</b>	S19
<b>14</b>	S20
<b>17a and 17b</b>	S21–S22
<b>20a and 21a</b>	S23–S24
<b>20b</b>	S25
<b>21b</b>	S26
<b>III. References for Supporting Information</b>	S27
<b>IV. Copies of <math>^1\text{H}</math>, <math>^{13}\text{C}</math>, and 2D NMR Spectra</b>	S28–S94
<b>11</b>	S28–S32
<b>12a</b>	S33–S37
<b>SI-1</b>	S38–S42
<b>12b</b>	S43–S47
<b>SI-2</b>	S48–S52

<b>12c</b>	S53–S54
<b>SI-3</b>	S55
<b>12d</b>	S56–S57
<b>SI-4</b>	S58–S59
<b>12e</b>	S60–S61
<b>SI-5</b>	S62–S63
<b>12f</b>	S64–S65
<b>SI-6</b>	S66–S67
<b>12g</b>	S68–S69
<b>SI-7</b>	S70–S71
<b>14</b>	S72–S74
<b>17a and 17b</b>	S75–S76
<b>17b pure</b>	S77–S78
<b>20a</b>	S79–S82
<b>21a</b>	S83–S84
<b>20b</b>	S85–S89
<b>21b</b>	S90–S94

## I. General Experimental Protocols

**$^{13}\text{C}$  and  $^1\text{H}$  NMR spectra** were recorded on a Bruker HD-500, AV-500, AV-400, or AX-400 spectrometer. Proton chemical shifts are referenced to TMS ( $\delta$  0.00 ppm) in  $\text{CDCl}_3$  solutions and to the residual  $\text{CHD}_5$  ( $\delta$  7.16 ppm) in benzene- $d_6$  solutions. A non-first order multiplet, doublet, or doublet of doublets in a  $^1\text{H}$  NMR spectrum is denoted as a 'nfom', 'nfod', or 'nfodd', respectively. For the latter two, the coupling constant is listed as an apparent value ( $J_{app}$ ), because the spacing between the two major lines for the population of molecules having magnetically equivalent protons (ca. 50%) is actually the value of  $J_o + J_p$ . Resonances are reported in the following format: chemical shift (ppm) [multiplicity, coupling constant (s) (in Hz), integral value (to the nearest integer), and assignment of the substructural environment within the structure]. First-order coupling constants were analyzed using methods we have published elsewhere.<sup>1,2</sup> The  $^{13}\text{C}$  NMR chemical shifts are taken from the "1D" spectrum where possible, although some were deduced from HMBC correlations. Carbon chemical shifts are referenced to  $\delta$  77.16 ppm in  $\text{CDCl}_3$  solutions and to  $\delta$  128.06 for  $\text{C}_6\text{D}_6$  solutions.

**Infrared spectra** were recorded using a Bruker Alpha II Spectrometer. Samples were prepared as thin films on a diamond window in the attenuated total reflectance (ATR) mode. Absorption maxima are given in  $\text{cm}^{-1}$ .

The high-resolution **mass spectrometry** (HRMS) measurements were made in the ESI mode using a Thermo Orbitrap Velos instrument (mass accuracy of  $\leq 3$  ppm). An external calibrant was used (Pierce<sup>TM</sup> LTQ) and the samples were directly injected into the ion source.

Medium pressure liquid **chromatography** (MPLC) was often used to purify newly synthesized materials. Hand-packed silica gel columns (normal-phase, 25-200 psi, 20-40  $\mu\text{m}$ , 60  $\text{\AA}$  pore size, Teledyne RediSep Rf Gold<sup>®</sup>) were used. The apparatus consisted of a Waters HPLC pump (model 510), a Gilson (111 UV) detector, and a Waters (R401) differential refractive index detector. Preparative flash chromatography was performed on columns packed with Agela silica gel (230-400 mesh). Thin layer chromatography (TLC) was performed on silica-gel coated, plastic-backed plates that were visualized by UV light and/or by a solution of potassium permanganate and heating.

The indicated reaction temperature refers to the temperature of the external cooling or heating bath. HDDA reactions, including those performed at temperatures higher than the boiling point of the reaction solvent, were done in a screw-top culture tube that was capped with an inert, Teflon<sup>®</sup>-lined closure.

Poly-yne substrates **8**<sup>3</sup>, **19a**<sup>4</sup>, and **19b**<sup>4</sup> were synthesized according to reported methods.

## II. Preparation procedures and characterization data for all compounds

### A. General Procedure for trapping of HDDA-generated arynes with imines

The polyynes precursor (1 equiv) and the imine (1-3 equiv) were combined in a screw-capped culture tube. 1,2-Dichloroethane was added (0.05 M) and the resulting solution was placed in an oil bath maintained at 90 °C and allowed to react overnight. Subsequently, the solvent was removed under reduced pressure, and the crude material was purified using MPLC with the elution solvent mixture indicated for each compound.


### B. General Procedure for oxidation of 1,4-dihydroacridines to their respective acridines

A scintillation vial or a culture tube was charged with a stir bar and the respective 1,4-dihydroacridine (1 equiv). Chloroform or dichloromethane (0.005 M) was added, along with MnO<sub>2</sub> (ca. 10-20 equiv). The resulting slurry was allowed to stir at ambient temperature until the reaction was observed to be complete by TLC analysis. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo.

### C. General Procedure for one-pot synthesis of acridines from HDDA-generated benzyne and imines

The HDDA polyynes precursor (1 equiv) and the imine (1-3 equiv) were added to a screw-cap culture tube. 1,2-Dichloroethane was added (0.05 M), and the resulting solution was placed in an oil bath maintained at 90 °C and allowed to react overnight. MnO<sub>2</sub> (ca. 10-20 equiv) and a stir bar were added. The slurry was then stirred at ambient temperature until the reaction was observed to be complete by TLC. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo.

**10,11-Dimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (11)**



*N*-Benzylideneaniline (**2a**) was prepared according to a reported procedure.<sup>5</sup>

Following general procedure A, 1-(4,5-dimethoxy-2-(penta-1,3-diyn-1-yl)phenyl)-3-(trimethylsilyl)prop-2-yn-1-one (**8**, 0.024 g, 0.074 mmol, 1 equiv), (*E*)-*N*,1-diphenylmethanimine (**2a**, 0.015 g, 0.083 mmol, 1.1 equiv), and dichloroethane (2 mL) were used to prepare the 1,4-dihydroacridine **11**. Purification of the crude product by MPLC (2:1 hexanes:EtOAc) yielded **11** (0.038 g, 0.076 mmol, 98%) as an orange crystalline solid.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.45 (d, *J* = 7.8, 1.4 Hz, 1H, *H1*), 7.29 (mfod, *J*<sub>app</sub> = 7.5 Hz, 2H, *ArH<sub>o</sub>*), 7.22 (mfodd, *J*<sub>app</sub> = 7.7, 7.7 Hz, 2H, *PhH<sub>m</sub>*), 7.126 (ddd, *J* = 7.4, 7.4, 1.5 Hz, 1H, *H3*), 7.125 (tt, *J* = 7.4, 1.5 Hz, 1H, *ArH<sub>p</sub>*), 7.10 (s, 1H, *H9*), 7.09 (s, 1H, *H12*), 6.95 (dd, *J* = 7.4, 7.4, 1.1 Hz, 1H, *H2*), 6.81 (dd, *J* = 7.9, 1.3 Hz, 1H, *H4*), 6.48 (s, 1H, *NH*), 5.77 (s, 1H, *H13*), 3.90 (s, 3H, *OCH<sub>3</sub>*), 3.86 (s, 3H, *OCH<sub>3</sub>*), 2.45 (s, 3H, *ArCH<sub>3</sub>*), and 0.46 (s, 9H, *Si(CH<sub>3</sub>)<sub>3</sub>*).


<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): 193.6, 153.0, 149.0, 144.7, 143.1, 142.6, 141.2, 137.6, 137.5, 133.8, 129.1, 128.70, 128.67, 127.8, 127.1, 127.0, 125.3, 123.9, 122.3, 118.8, 115.2, 107.8, 106.7, 56.6, 56.2, 44.7, 18.2, and 3.2.

HRMS (ESI-TOF): Calcd for C<sub>32</sub>H<sub>32</sub>NO<sub>3</sub>Si<sup>+</sup> [*M*+*H*<sup>+</sup>]<sup>+</sup> requires 506.2146; found 506.2150.

IR (neat): 3440, 3390, 3059, 3001, 2924, 2853, 2359, 2342, 2069, 2034, 1976, 1961, 1944, 1694, 1605, 1577, 1546, 1489, 1465, 1432, 1416, 1375, 1343, 1324, 1299, 1283, 1259, 1245, 1215, 1173, 1158, 1091, 1045, 1027, 991, 936, 873, 854, 797, 771, 751, 727, 699, 676, 645, 630, 613, 599, 575, 519, 493, 449, and 408 cm<sup>-1</sup>.

mp: 249-250 °C.

**10,11-Dimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12a)**



Following general procedure C, 1-(4,5-dimethoxy-2-(penta-1,3-diyn-1-yl)phenyl)-3-(trimethylsilyl)prop-2-yn-1-one (**8**, 0.010 g, 0.030 mmol, 1 equiv), (*E*)-*N*,1-diphenylmethanimine (**2a**, 0.007 g, 0.038 mmol, 1.3 equiv), MnO<sub>2</sub> (xs), and dichloroethane (2 mL) were used to prepare acridine **12a**. Purification of the crude product yielded acridine **12a** (0.011 g, 0.022 mmol, 71%) as a purple crystalline solid.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 8.26 (d, *J* = 8.6 Hz, 1H, *H*<sub>4</sub>), 8.14 (d, *J* = 8.9 Hz, 1H, *H*<sub>1</sub>), 7.78 (mfod, *J*<sub>app</sub> = 7.2 Hz, 2H, Ph*H*<sub>o</sub>), 7.77 (br dd, *J* = 8.8, 6.8 Hz, 1H, *H*<sub>3</sub>), 7.56 (mfodd, *J*<sub>app</sub> = 7.5, 7.5 Hz, 2H, Ph*H*<sub>m</sub>), 7.53 (tt, *J* = 6.9, 1.7 Hz, 1H, Ph*H*<sub>p</sub>), 7.48 (br dd, *J* = 8.6, 6.6 Hz, 1H, *H*<sub>2</sub>), 7.04 (s, 1H, *H*<sub>9</sub>), 5.64 (s, 1H, *H*<sub>12</sub>), 3.83 (s, 3H, C10OCH<sub>3</sub>), 3.51 (s, 3H, C11OCH<sub>3</sub>), 3.06 (s, 1H, ArCH<sub>3</sub>), and 0.51 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).


**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 195.4, 153.0, 150.6, 149.0, 148.0, 146.9, 145.1, 143.0, 140.1, 138.6, 137.3, 136.1, 132.8, 130.9, 130.3, 129.5, 129.0, 126.7, 126.5, 125.2, 125.0, 120.8, 109.3, 106.5, 56.7, 56.1, 20.7, and 2.7.

**HRMS** (ESI-TOF): Calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>3</sub>Si<sup>+</sup> [M+H<sup>+</sup>]<sup>+</sup> requires 504.1989; found 504.1983.

**IR** (neat): 3062, 2956, 2922, 2852, 2357, 2171, 2099, 2041, 2023, 1984, 1758, 1709, 1595, 1579, 1498, 1463, 1442, 1418, 1405, 1376, 1336, 1285, 1250, 1224, 1180, 1144, 1109, 1059, 1026, 1012, 972, 896, 842, 816, 799, 764, 734, 702, 671, 642, 619, 604, 568, 544, 519, 507, and 412 cm<sup>-1</sup>.

**mp**: 96-97 °C.

**10,11-Dimethoxy-6-methyl-13-(4-nitrophenyl)-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-1):**



1-(4-Nitrophenyl)-*N*-phenylmethanimine (**2b**) was prepared according to a reported procedure.<sup>6</sup>

Following general procedure A, 1-(4,5-dimethoxy-2-(penta-1,3-dien-1-yl)phenyl)-3-(trimethylsilyl)prop-2-yn-1-one (**8**, 0.009 g, 0.029 mmol, 1 equiv), (*E*)-1-(4-nitrophenyl)-*N*-phenylmethanimine (**2b**, 0.023 g, 0.093 mmol, 3.2 equiv), and dichloroethane (2 mL) were used to prepare the 1,4-dihydroacridine **SI-1**. Purification of the crude product by MPLC (2:1 hexanes:EtOAc) yielded **SI-1** (0.011 g, 0.020 mmol, 68%) as an orange amorphous solid.


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.09 (nfod,  $J_{app}$  = 8.6 Hz, 2H, *H*3' and *H*5'), 7.43 (nfod,  $J_{app}$  = 9.0 Hz, 2H, *H*2' and *H*6'), 7.43 (dd,  $J$  = 7.5, 1.5 Hz, 1H, *H*1), 7.18 (ddd,  $J$  = 7.6, 7.6, 1.3 Hz, 1H, *H*3), 7.12 (s, 1H, *H*9), 7.02 (s, 1H, *H*12), 6.99 (ddd,  $J$  = 7.5, 7.5, 1.8 Hz, 1H, *H*2), 6.86 (dd,  $J$  = 7.6, 1.8 Hz, 1H, *H*4), 6.53 (s, 1H, *NH*), 5.90 (s, 1H, *H*13), 3.92 (s, 3H, OCH<sub>3</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 2.46 (s, 3H, ArCH<sub>3</sub>), and 0.46 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 193.2, 153.1, 151.4, 149.4, 146.9, 142.7, 142.4, 142.1, 137.8, 137.0, 134.0, 128.8, 128.6, 128.5, 127.9, 125.8, 124.4, 122.6, 122.0, 117.3, 115.5, 107.3, 107.0, 56.6, 56.3, 44.6, 18.2, and 3.2.

HRMS (ESI-TOF): Calcd for C<sub>32</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub>Si<sup>+</sup> [M+H<sup>+</sup>]<sup>+</sup> requires 551.1997; found 551.1958 (major ion) and Calcd for C<sub>32</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub>Si<sup>+</sup> [M-2H+H<sup>+</sup>]<sup>+</sup> requires 549.1840; found 549.1817.

IR (neat): 3433, 3103, 3057, 3002, 2943, 2899, 2835, 2452, 2346, 2220, 2122, 1925, 1696, 1604, 1593, 1577, 1546, 1521, 1489, 1465, 1431, 1415, 1374, 1344, 1299, 1282, 1259, 1244, 1214, 1110, 1090, 1044, 1022, 1014, 990, 937, 852, 797, 770, 751, 711, 696, 677, 642, 628, 603, 576, 544, 519, 494, 457, and 433 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-13-(4-nitrophenyl)-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12b):**



Following General Procedure B, 10,11-dimethoxy-6-methyl-13-(4-nitrophenyl)-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (**SI-1**, 0.009 g, 0.015 mmol, 1 equiv),  $\text{MnO}_2$  (xs), and  $\text{CHCl}_3$  (10 mL) were used to prepare acridine **12b**. Purification of the crude product yielded **12b** (0.008 g, 0.014 mmol, 90%) as a purple amorphous solid.

$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.42 (nfod,  $J_{\text{app}} = 8.7$  Hz, 2H,  $H_{3'}$  and  $H_{5'}$ ), 8.30 (dd,  $J = 8.3$ , 1.1 Hz, 1H,  $H_4$ ), 7.99 (nfod,  $J_{\text{app}} = 8.7$  Hz, 2H,  $H_{2'}$  and  $H_{6'}$ ), 7.98 (dd,  $J = 8.3$ , 1.1 Hz, 1H,  $H_{11}$ ), 7.80 (ddd,  $J = 8.8$ , 6.5, 1.3 Hz, 1H,  $H_3$ ), 7.53 (ddd,  $J = 8.8$ , 6.5, 1.3 Hz, 1H,  $H_2$ ), 7.06 (s, 1H,  $H_9$ ), 5.60 (s, 1H,  $H_{12}$ ), 3.83 (s, 3H,  $\text{C}_{10}\text{-OCH}_3$ ), 3.50 (s, 3H,  $\text{C}_{11}\text{-OCH}_3$ ), 3.07 (s, 3H,  $\text{ArCH}_3$ ), and 0.51 (s, 9H,  $\text{Si}(\text{CH}_3)_3$ ).


$^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ ): 194.9, 152.9, 150.3, 148.9, 148.6, 148.1, 147.4, 145.0, 141.8, 141.7, 139.3, 137.9, 136.6, 133.6, 131.3, 130.5, 127.7, 125.4, 125.2, 124.3, 124.0, 120.1, 108.9, 107.1, 56.6, 56.2, 20.6, and 2.6.

**HRMS** (ESI-TOF): Calcd for  $\text{C}_{32}\text{H}_{29}\text{N}_2\text{O}_5\text{Si}^+$   $[\text{M}+\text{H}]^+$  requires 549.1840; found 549.1827.

**IR** (neat): 3104, 3074, 2999, 2945, 2900, 2838, 2702, 2456, 2036, 2007, 1974, 1950, 1707, 1598, 1586, 1524, 1493, 1460, 1406, 1379, 1367, 1346, 1295, 1248, 1217, 1182, 1165, 1133, 1099, 1060, 1014, 981, 944, 884, 854, 812, 793, 762, 735, 704, 680, 662, 644, 627, 619, 606, 580, 569, 530, 493, 485, 451, and  $414\text{ cm}^{-1}$ .



**10,11-Dimethoxy-13-(4-methoxyphenyl)-6-methyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-2)**



1-(4-Methoxyphenyl)-*N*-phenylmethanimine (**2c**) was prepared according to a reported procedure.<sup>7</sup>

Following General Procedure A, 1-(4,5-dimethoxy-2-(penta-1,3-diyn-1-yl)phenyl)-3-(trimethylsilyl)prop-2-yn-1-one (**8**, 0.020 g, 0.063 mmol, 1 equiv), (*E*)-1-(4-methoxyphenyl)-*N*-phenylmethanimine (**2c**, 0.041 g, 0.179 mmol, 2.9 equiv), and dichloroethane (2 mL) were used to prepare the 1,4-dihydroacridine **SI-2**. Purification of the crude product by MPLC (2:1 hexanes:EtOAc) yielded **SI-2** (0.027 g, 0.048 mmol, 78%) as an orange amorphous solid.


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.41 (dd, *J* = 7.6, 1.4 Hz, 1H, *H1*), 7.18 (nfod, *J*<sub>app</sub> = 8.8 Hz, 2H, *H2'* and *H6'*), 7.12 (ddd, *J* = 7.6, 7.6, 1.5 Hz, 1H, *H3*), 7.098 (s, 1H, *H9* or *H12*), 7.096 (s, 1H, *H9* or *H12*), 6.95 (ddd, *J* = 7.5, 7.5, 1.2 Hz, 1H, *H2*), 6.80 (dd, *J* = 7.9, 1.2 Hz, 1H, *H4*), 6.75 (nfod, *J*<sub>app</sub> = 8.8 Hz, 2H, *H3'* and *H5'*), 6.47 (s, 1H, NH), 5.71 (s, 1H, *H13*), 3.91 (s, 3H, OCH<sub>3</sub>), 3.86 (s, 3H, OCH<sub>3</sub>), 3.68 (s, 3H, C4'-OCH<sub>3</sub>), 2.43 (s, 3H, ArCH<sub>3</sub>), and 0.46 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 193.6, 158.5, 153.0, 149.0, 143.0, 142.5, 141.1, 137.6, 137.5, 136.9, 133.7, 128.7, 128.6, 128.1, 127.7, 125.3, 124.2, 122.2, 119.1, 115.1, 114.4, 107.8, 106.6, 56.5, 56.2, 55.3, 18.2, and 3.2.

HRMS (ESI-TOF): Calcd for C<sub>33</sub>H<sub>32</sub>NO<sub>4</sub>Si<sup>+</sup> [M-2H+H<sup>+</sup>]<sup>+</sup> requires 534.2095; found 534.2078.

IR (neat): 3445, 3388, 3055, 2999, 2948, 2902, 2835, 2358, 2344, 2197, 2174, 2144, 2121, 2068, 2027, 2014, 1981, 1963, 1950, 1926, 1693, 1607, 1577, 1546, 1507, 1489, 1464, 1431, 1415, 1374, 1342, 1324, 1298, 1283, 1246, 1214, 1179, 1110, 1090, 1030, 990, 874, 846, 797, 788, 770, 748, 699, 676, 646, 631, 607, 588, 557, 529, 487, 474, 453, 435, and 417 cm<sup>-1</sup>.

**10,11-Dimethoxy-13-(4-methoxyphenyl)-6-methyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12c)**



Following General Procedure B, 10,11-dimethoxy-13-(4-methoxyphenyl)-6-methyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (**SI-2**, 0.025 g, 0.045 mmol, 1 equiv),  $\text{MnO}_2$  (xs), and  $\text{CHCl}_3$  (10 mL) were used to prepare acridine **12c**. Purification of the crude product yielded **12c** (0.021 g, 0.039 mmol, 86%) as a purple amorphous solid.


$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.25 (dd,  $J = 8.7, 1.2$  Hz, 1H,  $H_4$ ), 8.16 (dd,  $J = 8.9, 1.2$  Hz, 1H,  $H_1$ ), 7.75 (ddd,  $J = 8.7, 6.5, 1.3$  Hz, 1H,  $H_3$ ), 7.69 (nfod,  $J_{\text{app}} = 8.7$  Hz, 2H,  $H_2'$  and  $H_6'$ ), 7.47 (ddd,  $J = 8.9, 6.5, 1.3$  Hz, 1H,  $H_2$ ), 7.07 (nfod,  $J_{\text{app}} = 8.8$  Hz, 2H,  $H_3'$  and  $H_5'$ ), 7.05 (s, 1H,  $H_9$ ), 5.67 (s, 1H,  $H_{12}$ ), 3.87 (s, 3H,  $\text{OCH}_3$ ), 3.84 (s, 3H,  $\text{OCH}_3$ ), 3.55 (s, 3H,  $\text{C}_{11}\text{-OCH}_3$ ), 3.05 (s, 3H,  $\text{Ar-CH}_3$ ), and 0.51 (s, 9H,  $\text{Si}(\text{CH}_3)_3$ ).

$^{13}\text{C NMR}$  (125 MHz,  $\text{CDCl}_3$ ): 195.4, 160.7, 153.1, 150.7, 149.0, 148.0, 146.8, 145.0, 143.2, 140.1, 137.0, 136.0, 134.0, 131.0, 130.9, 130.2, 126.5, 125.4, 125.3, 121.0, 114.5, 109.6, 106.4, 56.6, 56.1, 55.6, 20.6, and 2.6. (missing one aromatic C; one of the resonances at 134.0, 126.5, and 114.4 ppm is likely two non-resolved resonances)

**HRMS** (ESI-TOF): Calcd for  $\text{C}_{33}\text{H}_{32}\text{NO}_4\text{Si}^+$  [ $\text{M}+\text{H}^+$ ] $^+$  requires 534.2095; found 534.2081.

**IR** (neat): 3068, 3000, 2945, 2901, 2838, 2023, 1915, 1703, 1605, 1586, 1539, 1494, 1459, 1406, 1378, 1367, 1329, 1294, 1250, 1217, 1177, 1133, 1112, 1099, 1061, 1029, 1017, 949, 842, 813, 790, 763, 733, 701, 670, 652, 633, 621, 608, 588, 570, 529, 505, 493, 476, 450, 420, and 406  $\text{cm}^{-1}$ .

**10,11-Dimethoxy-6-methyl-2-nitro-13-phenyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-3):**



*N*-(4-Nitrophenyl)-1-phenylmethanimine (**2d**) was prepared according to a reported procedure with the modification that elevated temperature was used to increase the rate of imine formation.<sup>8</sup>


Triynone **8** (20 mg, 0.0616 mmol, 1 equiv) and the imine **2d** (45 mg, 0.185 mmol, 3 equiv) were added to a screw-capped culture tube containing freshly activated 4Å molecular sieves. 1,2-DCE was added (0.05 M) and the resulting solution was placed in an oil bath maintained at 85 °C and kept overnight. The solvent was partially removed under reduced pressure, chloroform was added, and the mixture was directly loaded onto the MPLC column and eluted (2:1 hexanes:EtOAc) to give **SI-3** (21 mg, 62%) as a dark red amorphous solid.

The extremely low solubility of this material, likely due to strong hydrogen bonding in the crystal lattice of this *p*-nitroaniline derivative, precluded obtaining a suitable <sup>13</sup>C NMR spectrum.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.39 (d, *J* = 2.6 Hz, 1H, *H1*), 8.05 (dd, *J* = 8.8, 2.5 Hz, 1H, *H3*), 7.34–7.30 (m, *PhH<sub>o</sub>* and *PhH<sub>m</sub>*), 7.18 (tt, *J* = 8.6, 1.5 Hz, *PhH<sub>p</sub>*), 7.11 (s, 1H, *H9* or *H12*), 7.04 (s, 1H, *H9* or *H12*), 6.91 (br s, 1H, *NH*), 6.88 (d, *J* = 8.9 Hz, 1H, *H4*), 5.81 (s, 1H, *H13*), 3.94 (s, 3H, *OCH<sub>3</sub>*), 3.87 (s, 3H, *OCH<sub>3</sub>*), 2.50 (s, 3H, *ArCH<sub>3</sub>*), and 0.47 (s, 9H, *Si(CH<sub>3</sub>)<sub>3</sub>*).

**HRMS** (ESI-TOF): Calcd for C<sub>32</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub>Si<sup>+</sup> [*M*+*H*<sup>+</sup>]<sup>+</sup> requires 551.1997; found 551.1945 (major ion) and Calcd for C<sub>32</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub>Si<sup>+</sup> [*M*-2*H*+*H*<sup>+</sup>]<sup>+</sup> requires 549.1840; found 549.1817 (minor ion).

**IR** (neat): 3379, 3084, 2954, 2904, 2852, 2368, 2136, 2074, 2041, 1952, 1700, 1675, 1600, 1576, 1545, 1522, 1490, 1457, 1427, 1408, 1375, 1321, 1298, 1244, 1213, 1191, 1086, 1045, 1023, 990, 967, 950, 864, 841, 797, 780, 769, 741, 675, 657, 639, 617, 607, 577, 550, 520, 495, 450, 420, and 409 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-2-nitro-13-phenyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12d):**

The acridine **12d** was synthesized according to General Procedure B: 14 mg of amine **SI-3** (1 equiv) and 22 mg of  $\text{MnO}_2$  (10 equiv). The reaction mixture was filtered through Celite® (DCM elution) to afford **12d** (12 mg, 82%) as a purple amorphous solid.


**$^1\text{H}$  NMR** (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  9.15 (d, 2.4 Hz, 1H,  $H_1$ ), 8.47 (dd,  $J = 9.5, 2.3$  Hz, 1H,  $H_3$ ), 8.36 (d,  $J = 9.5$  Hz, 1H,  $H_4$ ), 7.81–7.77 (mfom, 2H,  $\text{Ph}H_o$ ), 7.66–7.62 (m, 3H,  $\text{Ph}H_m$  and  $\text{Ph}H_p$ ), 7.06 (s, 1H,  $H_9$ ), 5.60 (s, 1H,  $H_{12}$ ), 3.84 (s, 3H,  $\text{OCH}_3$ ), 3.51 (s, 3H,  $\text{OCH}_3$ ), 3.05 (s, 3H,  $\text{ArCH}_3$ ), and 0.52 (s, 9H,  $\text{Si}(\text{CH}_3)_3$ ).

**$^{13}\text{C}$  NMR** (126 MHz,  $\text{CDCl}_3$ ): 194.9, 153.3, 152.2, 149.6, 148.7, 148.5, 147.2, 145.6, 142.9, 139.6, 139.2, 138.3, 137.4, 132.8, 132.7, 130.6, 129.6, 125.0, 124.9, 123.2, 123.1, 121.4, 109.1, 106.7, 56.7, 56.2, 20.6, and 2.6.

**HRMS** (ESI-TOF): Calcd for  $\text{C}_{32}\text{H}_{29}\text{N}_2\text{O}_5\text{Si}^+ [\text{M}+\text{H}]^+$  requires 549.1840; found 549.1827.

**IR** (neat): 3058, 3001, 2943, 2903, 2851, 2194, 2152, 2069, 2021, 1977, 1707, 1620, 1602, 1585, 1560, 1540, 1518, 1494, 1465, 1456, 1417, 1401, 1370, 1335, 1293, 1246, 1218, 1182, 1159, 1131, 1104, 1086, 1064, 1028, 1014, 971, 928, 909, 867, 839, 814, 803, 788, 767, 738, 707, 679, 664, 642, 623, 586, 565, 542, 520, 494, 458, 433, and  $414\text{ cm}^{-1}$ .

**2,10,11-Trimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-4)**



*N*-(4-Methoxyphenyl)-1-phenylmethanimine (**2e**) was prepared according to a reported procedure.<sup>9</sup>

The dihydroacridine **SI-4** was synthesized according to General Procedure A using the tryne **8** (25 mg) and the imine **2e** (49 mg, 3 equiv). Purification by MPLC (2:1 hexanes:EtOAc) afforded (41 mg, 100%) as a red amorphous solid.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 7.29 (nfod,  $J_{app}$  = 8.2 Hz, 2H, ArH<sub>o</sub>), 7.22 (nfodd,  $J_{app}$  = 7.5, 7.5 Hz, 2H, PhH<sub>m</sub>), 7.12 (tt,  $J$  = 7.3, 1.4 Hz, 1H, ArH<sub>p</sub>), 7.09 (s, 1H, H<sub>9</sub>), 7.08 (s, 1H, H<sub>12</sub>), 6.99 (d,  $J$  = 2.6 Hz, 1H, H<sub>1</sub>), 6.75 (d,  $J$  = 8.6 Hz, 1H, H<sub>4</sub>), 6.70 (dd,  $J$  = 8.6, 2.7 Hz, 1H, H<sub>3</sub>), 6.39 (s, 1H, NH), 5.73 (s, 1H, H<sub>13</sub>), 3.90 (s, 3H, OCH<sub>3</sub>), 3.85 (s, 3H, OCH<sub>3</sub>), 3.78 (s, 3H, OCH<sub>3</sub>), 2.42 (s, 3H, ArCH<sub>3</sub>), and 0.46 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>): 193.4, 155.2, 152.9, 149.0, 144.6, 143.4, 142.6, 141.1, 137.4, 133.3, 131.5, 129.0, 128.8, 127.1, 127.0, 125.1, 124.8, 118.1, 115.9, 114.0, 113.4, 107.8, 106.6, 56.6, 56.2, 55.9, 45.0, 18.2, and 3.2.

**HRMS** (ESI-TOF): Calcd for C<sub>33</sub>H<sub>34</sub>NO<sub>4</sub>Si<sup>+</sup> [M+H<sup>+</sup>]<sup>+</sup> requires 536.2252; found 536.2219 (major ion) and Calcd for C<sub>33</sub>H<sub>32</sub>NO<sub>4</sub>Si<sup>+</sup> [M-2H+H<sup>+</sup>]<sup>+</sup> requires 534.2095; found 534.2084 (minor ion).

**IR** (neat): 3440, 3392, 3058, 3020, 2999, 2941, 2900, 2834, 2361, 2339, 2225, 2182, 2153, 2028, 1957, 1692, 1602, 1575, 1546, 1492, 1462, 1442, 1411, 1374, 1343, 1309, 1284, 1259, 1245, 1212, 1173, 1164, 1153, 1131, 1118, 1091, 1043, 1029, 990, 952, 863, 841, 797, 768, 734, 701, 644, 627, 609, 567, 552, 535, 514, 493, 459, 451, 416, and 405 cm<sup>-1</sup>.

**2,10,11-Trimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12e):**



The acridine **12e** was synthesized according to General Procedure B (36 mg of amine **SI-4**). The reaction mixture was filtered through Celite® (DCM elution) to afford **12e** (36 mg, quant.) as a purple oil. This material was purified by MPLC on silica gel (2:1 hexanes:EtOAc) to give **12e** (34 mg, 94%) as a purple amorphous solid.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 8.15 (d, 9.4 Hz, 1H, *H*<sub>4</sub>), 7.78 (nfod, *J*<sub>app</sub> = 6.9 Hz, 2H, *PhH*<sub>o</sub>), 7.55 (nfodd, *J*<sub>app</sub> = 7.1, 7.1 Hz, 2H, *PhH*<sub>m</sub>), 7.49 (tt, *J* = 7.3, 1.5 Hz, 1H, *PhH*<sub>p</sub>), 7.45 (br dd, *J* = 9.4, 2.7 Hz, 1H, *H*<sub>3</sub>), 7.37 (d, *J* = 2.6 Hz, 1H, *H*<sub>11</sub>), 7.03 (s, 1H, *H*<sub>9</sub>), 5.65 (s, 1H, *H*<sub>12</sub>), 3.831 (s, 3H, C2- or C10-OCH<sub>3</sub>), 3.828 (s, 3H, C2- or C10-OCH<sub>3</sub>), 3.52 (s, 3H, C11-OCH<sub>3</sub>), 3.04 (s, 1H, ArCH<sub>3</sub>), and 0.50 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 195.5, 158.0, 153.0, 149.2, 147.9, 146.9, 146.2, 142.4, 142.3, 140.3, 139.1, 137.5, 134.9, 132.5, 132.4, 129.3, 129.0, 126.0, 125.3, 125.0, 121.0, 109.2, 106.4, 101.9, 56.6, 56.1, 55.5, 20.6, and 2.7.

**HRMS** (ESI-TOF): Calcd for C<sub>33</sub>H<sub>32</sub>NO<sub>4</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 534.2095; found 534.2079.

**IR** (neat): 3120, 3057, 2999, 2947, 2902, 2835, 2356, 2194, 2048, 1970, 1703, 1604, 1586, 1552, 1524, 1512, 1493, 1467, 1442, 1406, 1375, 1369, 1354, 1293, 1261, 1247, 1227, 1210, 1171, 1157, 1120, 1102, 1066, 1028, 1016, 976, 868, 839, 831, 808, 792, 768, 739, 706, 676, 654, 636, 613, 587, 577, 554, 540, 521, 497, 460, 437, 424, and 410 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-2-nitro-13-(4-nitrophenyl)-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-5)**



Following general procedure A, 1-(4,5-dimethoxy-2-(penta-1,3-diyne-1-yl)phenyl)-3-(trimethylsilyl)prop-2-yn-1-one (**8**, 0.025 g, 0.078 mmol, 1 equiv), *N*,1-bis(4-nitrophenyl)methanimine (**2f**, 0.063 g, 0.23 mmol, 3.0 equiv), and 1,2-dichloroethane (2 mL) were used to prepare the 1,4-dihydroacridine **SI-5**. Purification of the crude product by MPLC (3:1 hexanes:EtOAc) yielded **SI-5** (0.009 g, 0.015 mmol, 19%) as an orange amorphous solid.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 8.38 (d, *J* = 2.4 Hz, 1H, ArH1), 8.14 (mfod, *J*<sub>app</sub> = 8.8 Hz, 2H, ArH3' and ArH5'), 8.10 (dd, *J* = 8.9, 2.5 Hz, 1H, H3), 7.47 (mfod, *J*<sub>app</sub> = 8.8 Hz, 2H, ArH2' and ArH6'), 7.14 (s, 1H, ArH9), 6.97 (s, 1H, ArH12), 6.95 (br s, 1H, NH), 6.92 (d, *J* = 8.9 Hz, 1H, H4) 5.95 (s, 1H, H13), 3.96 (s, 3H, OCH<sub>3</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 2.51 (s, 3H, ArCH<sub>3</sub>), and 0.47 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 192.6, 153.6, 150.3, 149.8, 147.4, 143.0, 143.0, 142.5, 142.2, 140.3, 136.6, 135.9, 128.5, 127.9, 126.7, 125.2, 124.8, 124.8, 122.3, 116.7, 115.3, 107.2, 107.1, 56.7, 56.3, 44.2, 18.3, and 3.1.


**HRMS** (ESI-TOF): Calcd for C<sub>32</sub>H<sub>30</sub>N<sub>3</sub>O<sub>7</sub>Si<sup>+</sup> [M+H<sup>+</sup>]<sup>+</sup> requires 596.1848; found 596.1814.

**IR** (neat): 3628, 3380, 3006, 2946, 2837, 1890, 1700, 1602, 1551, 1523, 1495, 1462, 1409, 1375, 1345, 1327, 1301, 1245, 1213, 1111, 1089, 1046, 1015, 990, 949, 865, 854, 833, 797, 773, 726, 699, 675, 667, 640, 609, 581, 565, 555, 522, 492, 482, 455, 435, and 412 cm<sup>-1</sup>.

*N*,1-bis(4-Nitrophenyl)methanimine (**2f**) was prepared according to the following procedure:

*p*-Nitroaniline (0.30 g, 2.2 mmol, 1 equiv) and *p*-nitrobenzaldehyde (0.33 g, 2.2 mmol, 1 equiv) were added to a 50 mL round-bottom flask and suspended in 20 mL of toluene. The solution was heated to reflux, during which time it became homogeneous, for 12 hours. The reaction solution was allowed to cool to room temperature. During this time, a yellow solid crystallized from the solution. The crystals were collected via vacuum filtration and washed with cold hexanes. Yellow needles of *N*,1-bis(4-nitrophenyl)methanimine (**2f**, ca. 0.5 g) were obtained and used without further purification. The <sup>1</sup>H NMR spectral data were consistent with previously reported data.<sup>10</sup>

**10,11-Dimethoxy-6-methyl-2-nitro-13-(4-nitrophenyl)-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (12f):**



Following General Procedure B, 10,11-dimethoxy-6-methyl-2-nitro-13-(4-nitrophenyl)-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (**SI-5**, 0.009 g, 0.015 mmol, 1 equiv), MnO<sub>2</sub> (xs), and CHCl<sub>3</sub> (10 mL) were used to prepare acridine **12f**. This oxidation reaction was accompanied by formation of a second, bright yellow compound of higher polarity, which required separation by MPLC (3:1 hexanes:EtOAc). This byproduct was not fully identified, but its <sup>1</sup>H NMR spectrum suggested that, at least, the aromatic methyl group had been oxidized to an aldehyde. Purification of the crude product yielded **12f** (0.004 g, 0.007 mmol, 56%) as a dark green amorphous solid.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 8.99 (d, *J* = 2.4 Hz, 1H, *H1*), 8.52 (dd, *J* = 9.4, 2.4 Hz, 1H, *H3*), 8.50 (nfod, *J*<sub>app</sub> = 8.8 Hz, 2H, *H3'* and *H5'*), 8.42 (d, *J* = 9.4 Hz, 1H, *H4*), 8.01 (nfod, *J*<sub>app</sub> = 8.7 Hz, 2H, *H2'* and *H6'*), 7.08 (s, 1H, *H9*), 5.56 (s, 1H, *H12*), 3.84 (s, 3H, OCH<sub>3</sub>), 3.50 (s, 3H, OCH<sub>3</sub>), 3.07 (s, 1H, ArCH<sub>3</sub>), and 0.53 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).


**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 194.4, 153.2, 151.9, 149.4, 149.0, 148.7, 147.8, 146.1, 145.3, 143.5, 141.8, 139.8, 138.9, 138.8, 133.5, 133.3, 125.2, 124.5, 123.4, 123.3, 122.6, 120.9, 108.7, 107.3, 56.6, 56.2, 20.7, and 2.5.

**HRMS** (ESI-TOF): Calcd for C<sub>32</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 594.1691; found 594.1676.

**IR** (neat): 3103, 3078, 3000, 2944, 2902, 2873, 2854, 2840, 1948, 1707, 1620, 1599, 1586, 1561, 1521, 1494, 1464, 1455, 1416, 1401, 1347, 1336, 1294, 1246, 1217, 1181.3, 1158.4, 1132, 1108, 1086, 1065, 1012, 990, 925, 906, 869, 854, 838, 813, 800, 787, 755, 726, 704, 682, 667, 652, 639, 606, 586, 566, 542, 519, 495, 484, 453, and 416 cm<sup>-1</sup>.



**2,10,11-Trimethoxy-13-(4-methoxyphenyl)-6-methyl-7-(trimethylsilyl)-5,13-dihydro-8H-indeno[1,2-a]acridin-8-one (SI-6)**



*N,N'*-bis(4-Methoxyphenyl)methanimine (**2g**) was prepared according to a reported procedure.<sup>11</sup>

The dihydroacridine **SI-6** was synthesized according to General Procedure A using the tryne **8** (25 mg) and the imine **2g** (56 mg, 3 equiv). Purification by MPLC (2:1 hexanes:EtOAc) afforded (38 mg, 88%) as a red amorphous solid.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>): δ 7.18 (nfod,  $J_{app}$  = 8.7 Hz, 2H, ArH2' and ArH6'), 7.099 (s, 1H, ArH9 or ArH12), 7.096 (s, 1H, ArH9 or ArH12), 6.97 (d,  $J$  = 2.5 Hz, 1H, H1), 6.76 (nfod,  $J_{app}$  = 8.8 Hz, 2H, ArH3' and ArH5'), 6.75 (d,  $J$  = 8.6 Hz, 1H, H4), 6.72 (dd,  $J$  = 8.6, 2.7 Hz, 1H, H3), 6.36 (s, 1H, NH), 5.68 (s, 1H, H13), 3.92 (s, 3H, OCH<sub>3</sub>), 3.86 (s, 3H, OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>), 3.69 (s, 3H, OCH<sub>3</sub>), 2.42 (s, 3H, ArCH<sub>3</sub>), and 0.45 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>): 193.5, 158.5, 155.3, 152.9, 149.0, 143.4, 142.6, 141.0, 137.4, 136.8, 133.3, 131.5, 128.8, 128.1, 125.2, 125.0, 118.4, 115.9, 114.4, 114.0, 113.3, 107.8, 106.6, 56.6, 56.2, 55.9, 55.3, 44.1, 18.2, and 3.2.

**HRMS** (ESI-TOF): Calcd for C<sub>34</sub>H<sub>34</sub>NO<sub>5</sub>Si<sup>+</sup> [M-2H]<sup>+</sup> requires 564.2201; found 564.2193 (major ion) and Calcd for C<sub>34</sub>H<sub>36</sub>NO<sub>5</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 566.2357; found 566.2316 (minor ion).

**IR** (neat): 3440, 3386, 2998, 2948, 2904, 2834, 2337, 2320, 2074, 2009, 1732, 1689, 1604, 1576, 1506, 1492, 1442, 1413, 1374, 1343, 1309, 1285, 1177, 1152, 1131, 1111, 1091, 1032, 990, 952, 862, 839, 792, 739, 687, 642, 629, 607, 567, 544, 480, 447, and 409 cm<sup>-1</sup>.

**2,10,11-Trimethoxy-13-(4-methoxyphenyl)-6-methyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (**12g**):**



The acridine **12g** was synthesized according to General Procedure B (19 mg of amine **SI-6**). The reaction mixture was filtered through Celite<sup>®</sup> (DCM elution) to afford crude **12g** as a purple oil. This material was purified by MPLC on silica gel (1:1 hexanes:EtOAc) to give **12g** (17 mg, 89%) as a purple amorphous solid.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>): δ 8.14 (d, *J* = 9.3 Hz, 1H, *H*<sub>4</sub>), 7.70 (nfod, *J*<sub>app</sub> = 8.7 Hz, 2H, Ar*H*<sub>2'</sub> and Ar*H*<sub>6'</sub>), 7.45 (dd, *J* = 9.2, 2.7 Hz, 1H, *H*<sub>3</sub>), 7.39 (d, *J* = 2.6 Hz, 1H, *H*<sub>1</sub>), 7.07 (nfod, *J*<sub>app</sub> = 8.7 Hz, 2H, Ar*H*<sub>3'</sub> and Ar*H*<sub>5'</sub>), 7.05 (s, 1H, *H*<sub>9</sub>), 5.68 (s, 1H, *H*<sub>12</sub>), 3.87 (s, 3H, OCH<sub>3</sub>), 3.85 (s, 3H, OCH<sub>3</sub>), 3.84 (s, 3H, OCH<sub>3</sub>), 3.56 (s, 3H, OCH<sub>3</sub>), 3.04 (s, 1H, ArCH<sub>3</sub>), and 0.50 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>): 195.5, 160.5, 158.0, 153.1, 149.3, 147.9, 146.9, 146.2, 142.6, 142.3, 140.3, 137.3, 134.9, 133.6, 132.5, 131.4, 126.2, 125.4, 124.9, 121.3, 114.5, 109.6, 106.4, 102.0, 56.6, 56.1, 55.6, 55.6, 20.5, and 2.7.

**HRMS** (ESI-TOF): Calcd for C<sub>34</sub>H<sub>34</sub>NO<sub>5</sub>Si<sup>+</sup> [M-2H]<sup>+</sup> requires 564.2201; found 564.2182

**IR** (neat): 3057, 3000, 2836, 2682, 2544, 2437, 2355, 2254, 2044, 1915, 1701, 1623, 1604, 1585, 1513, 1492, 1464, 1440, 1405, 1291, 1246, 1223, 1207, 1175, 1115, 1099, 1066, 1026, 1014, 868, 807, 766, 646, 612, 489, and 424 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-5,13-dihydro-8H-benzo[h]indeno[1,2-a]acridin-8-one (SI-7)**



*N*-(Naphthalen-1-yl)-1-phenylmethanimine (**13**) was prepared according to a reported procedure.<sup>12</sup>

Following general procedure A, triynone **8** (0.010 g, 0.030 mmol, 1 equiv), (*E*)-*N*-(naphthalen-1-yl)-1-phenylmethanimine (**13**, 0.023 g, 0.10 mmol, 3.3 equiv), and dichloroethane (1 mL) were used to prepare the 1,4-dihydroacridine **SI-7**. Purification of the crude product by MPLC (2:1 hexanes:EtOAc) yielded **SI-7** (0.016 g, 0.029 mmol, 98%) as an orange amorphous solid.


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.814 (dd, *J* = 7.9, 0.9 Hz, 1H, *H1* or *H4*), 7.809 (d, *J* = 8.0, 1.6 Hz, 1H, *H1* or *H4*), 7.57 (d, *J* = 8.4 Hz, 1H, *H14*), 7.55 (dd, *J* = 8.4, 6.8, 1.4 Hz, 1H, *H2* or *H3*), 7.47 (dd, *J* = 8.1, 6.8, 1.2 Hz, 1H, *H2* or *H3*), 7.47 (br d, *J* = 8.5 Hz, 1H, *H15*), 7.35 (mfod, *J*<sub>app</sub> = 7.3 Hz, 2H, *PhH<sub>o</sub>*), 7.27 (s, 1H, *NH*), 7.22 (mfodd, *J*<sub>app</sub> = 7.5, 7.5 Hz, 2H, *PhH<sub>m</sub>*), 7.15 (s, 1H, *H9* or *H12*), 7.11 (s, 1H, *H9* or *H12*), 7.13 (tt, *J* = 7.7, 1.5 Hz, 1H, *PhH<sub>p</sub>*), 5.90 (s, 1H, *H13*), 3.93 (s, 3H, *OCH<sub>3</sub>*), 3.87 (s, 3H, *OCH<sub>3</sub>*), 2.62 (s, 3H, *ArCH<sub>3</sub>*), and 0.49 (s, 9H, *Si(CH<sub>3</sub>)<sub>3</sub>*).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): 193.6, 153.1, 149.1, 144.9, 142.7, 142.6, 141.2, 137.5, 134.4, 133.2, 131.8, 129.11, 129.08, 128.6, 127.2, 127.1, 126.8, 126.2, 125.97, 125.95, 122.2, 122.0, 119.0, 118.6, 118.2, 107.8, 106.7, 56.6, 56.2, 45.2, 18.2, and 3.2.

HRMS (ESI-TOF): Calcd for C<sub>36</sub>H<sub>32</sub>NO<sub>3</sub>Si<sup>+</sup> [*M*-2H]<sup>+</sup> requires 554.2146; found 554.2132 (most intense ion) and Calcd for C<sub>36</sub>H<sub>34</sub>NO<sub>3</sub>Si<sup>+</sup> [*M*+H]<sup>+</sup> requires 556.2302; found 556.2260 (minor ion).

IR (neat): 3467, 3370, 3290, 3057, 3002, 2935, 2904, 854, 2837, 2359, 2183, 2123, 2048, 2007, 1977, 1949, 1712, 1694, 1614, 1578, 1550, 1516, 1492, 1460, 1406, 1375, 1349, 1310, 1293, 1277, 1251, 1214, 1173, 1130, 1094, 1018, 971, 946, 853, 804, 793, 771, 752, 736, 715, 703, 679, 668, 643, 626, 598, 582, 563, 542, 527, 496, 443, 432, 421, and 409 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-13-phenyl-7-(trimethylsilyl)-8H-benzo[h]indeno[1,2-a]acridin-8-one (14)**



Acridine **14** was prepared according to General Procedure B starting with 16 mg of amine **SI-7**. Purification by MPLC (3:1 hexanes:EtOAc) afforded **14** (11 mg, 69%) as a purple amorphous solid.

**<sup>1</sup>H NMR** (500 MHz, C<sub>6</sub>D<sub>6</sub>): 9.47 (dd, *J* = 8.2, 1.2 Hz, 1H, *H*<sub>4</sub>), 7.79 (d, *J* = 9.4 Hz, 1H, *H*<sub>14</sub>), 7.63 (ddd, *J* = 8.2, 7.0, 1.3 Hz, 1H, *H*<sub>3</sub> or *H*<sub>2</sub>), 7.60 (dd, *J* = 7.9, 1.6 Hz, 1H, *H*<sub>1</sub>), 7.50 (ddd, *J* = 8.2, 7.0, 1.4 Hz, 1H, *H*<sub>3</sub> or *H*<sub>2</sub>), 7.39 (d, *J* = 9.4, 0.9 Hz, 1H, *H*<sub>15</sub>), 7.32–7.30 (nfom, 2H, *H*<sub>2</sub>' and *H*<sub>6</sub>'), 7.12 (s, 1H, *H*<sub>9</sub>), 7.02–6.97 (m, 3H, *H*<sub>3</sub>', *H*<sub>4</sub>' and *H*<sub>5</sub>'), 5.57 (s, 1H, *H*<sub>12</sub>), 3.39 (s, 3H, OCH<sub>3</sub>), 3.23 (s, 3H, OCH<sub>3</sub>), 3.20 (s, 1H, ArCH<sub>3</sub>), and 0.79 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).


**<sup>13</sup>C NMR** (126 MHz, C<sub>6</sub>D<sub>6</sub>): δ 195.2, 153.9, 149.7, 149.3, 147.8, 147.2, 144.4, 143.1, 140.3, 138.9, 138.2, 136.8, 134.1, 132.9, 132.8, 129.7, 129.0, 128.8, 128.3, 127.9, 126.5, 126.1, 123.9, 123.5, 121.9, 110.4, 107.3, 56.4, 55.3, 21.0, and 3.1. (one aromatic signal wasn't observed, perhaps obscured by the solvent resonances).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 195.4, 153.1, 149.1, 148.1, 147.5, 146.9, 144.0, 142.6, 140.2, 138.7, 137.6, 136.6, 133.7, 132.8, 132.3, 129.5, 129.4, 129.0, 128.4, 127.7, 127.6, 126.0, 125.5, 123.6, 123.2, 121.4, 109.4, 106.4, 56.7, 56.1, 20.6, and 2.8.

**HRMS** (ESI-TOF): Calcd for C<sub>36</sub>H<sub>32</sub>NO<sub>3</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 554.2146; found 554.2128.

**IR** (neat): 3121, 3057, 2999, 2947, 2900, 2874, 2851, 2837, 2684, 2315, 2180, 2052, 1949, 1703, 1602, 1584, 1558, 1492, 1464, 1441, 1415, 1395, 1376, 1364, 1352, 1329, 1295, 1247, 1229, 1215, 1184, 1154, 1102, 1080, 1067, 1037, 1021, 1008, 978, 889, 850, 834, 803, 776, 747, 704, 683, 661, 637, 624, 600, 572, 552, 526, 501, 456, and 413 cm<sup>-1</sup>.

**10,11-Dimethoxy-6-methyl-7-(trimethylsilyl)-8H-indeno[1,2-a]acridin-8-one (17a)**  
and  
**3-(Dimethylamino)-6,7-dimethoxy-2-methyl-1-(trimethylsilyl)-9H-fluoren-9-one (17b)**



Amidinium **15** was prepared according to a reported procedure.<sup>13</sup>

Triynone **8** (20 mg, 0.0616 mmol, 1 equiv) and the formamidine **15** (28 mg, 0.185 mmol, 3 equiv) were added to a screw-capped culture tube containing freshly activated 4Å molecular sieves. Benzene was added (0.05 M) and the resulting solution was placed in an oil bath maintained at 85 °C and kept overnight. The solvent was then removed under reduced pressure, and the residue was purified by MPLC (2:1 hexanes:EtOAc) to give a coeluting mixture of **17a** (40% yield) and **17b** (56% yield).

**Data for 17a and 17b (a mixture of coeluting products in a ratio of 2:3)**

**Data for 17a, the acridine adduct, minor product:**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 9.23 (s, 1H, *H*13), 8.24 (dd, *J* = 8.9, 1.0 Hz, 1H, *H*4), 8.04 (dd, *J* = 8.6, 1.5 Hz, 1H, *H*1), 7.81 (ddd, *J* = 8.7, 6.6, 1.4 Hz, 1H, *H*3), 7.61 (s, 1H, *H*12), 7.57 (ddd, *J* = 8.1, 6.6, 1.3 Hz, 1H, *H*2), 7.23 (s, 1H, *H*9), 4.15 (s, 3H, OCH<sub>3</sub>), 3.96 (s, 3H, OCH<sub>3</sub>), 3.11 (s, 3H, ArCH<sub>3</sub>), and 0.52 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**HRMS** (ESI-TOF): Calcd for C<sub>26</sub>H<sub>26</sub>NO<sub>3</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 428.1676; found 428.1674.

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 195.2, 153.3, 150.1, 149.3, 146.0, 142.0, 138.7, 137.4, 135.8, 132.6, 131.2, 130.6, 128.4, 126.8, 126.8, 126.6, 122.0, 107.7, 107.3, 102.6, 56.8, 56.3, 20.2, and 3.2.


**Data for 17b, the amine-trapped adduct, major product:**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 7.11 (s, 1H, *H*8'), 7.01 (s, 1H, *H*5'), 6.93 (s, 1H, *H*4'), 4.01 (s, 3H, OCH<sub>3</sub>), 3.96 (s, 3H, OCH<sub>3</sub>), 3.11 (s, 3H, ArCH<sub>3</sub>), and 0.52 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>).

**HRMS** (ESI-TOF): Calcd for C<sub>21</sub>H<sub>28</sub>NO<sub>3</sub>Si<sup>+</sup> [M+H]<sup>+</sup> requires 370.1833; found 370.1832.

**<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):** 193.9, 157.6, 154.0, 149.5, 144.0, 143.9, 138.6, 135.7, 133.8, 127.7, 109.9, 106.8, 102.6, 56.5, 56.3, 43.9, 21.1, and 2.8.


An authentic sample of the amine-trapped product **17b** was also prepared using the following procedure:



Triynone **8** (20 mg, 0.0616 mmol, 1 equiv) and acetic acid (5.42  $\mu\text{L}$ , 0.092 mmol, 1.5 equiv) were added to a screw-capped culture tube. Benzene was added (0.05 M) and trimethylamine gas was bubbled through the mixture. This solution was placed in an oil bath maintained at 85  $^\circ\text{C}$  and kept overnight. The solvent was then removed under reduced pressure, and the residue was purified by MPLC (2:1 hexanes:EtOAc) to give **17b** as an orange oil.  $^1\text{H}$  and  $^{13}\text{C}$  spectrum for **17b** from this experiment were used as a reference to aid in the interpretation of the NMR data obtained from the sample of a mixture of the acridine and amine adducts **17a** and **17b** (from the above experiment).

**5-Methyl-2-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3-dihydro-1H-pyrrolo[3,4-a]acridine (20a)**

and

**5-Methyl-2-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3-dihydro-1H-pyrrolo[3,4-a]acridine (21a):**

This reaction was performed using general Procedure A: 20 mg of polyynes **19a** (1 equiv) and 55 mg of the imine **2a** (3 equiv). Purification by MPLC (2:1 hexanes:EtOAc) afforded the 1,4-dihydroacridine **20a** (18 mg, 42%) as a pale yellow crystalline solid along with the corresponding acridine **21a** (8 mg, 19%), which presumably arises through air oxidation, also as a yellow crystalline solid.

The assignment of the structure of the dihydroacridine **20a** was based upon observed (difference) nOe interactions between i) the amine proton (*NH*) with the adjacent aryl methyl group and the H7 aromatic proton; and ii) the methine proton (*H11*) with the adjacent methylene (*C1H2*) and H10 aromatic proton.

**Data for acridine 21a, the faster eluting minor product:**

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>): δ 8.28 (ddd, *J* = 8.8, 1.0, 1.0 Hz, 1H, *H7*), 7.75 [(ddd, *J* = 8.3, 6.3, 1.6 Hz, 1H, *H9*), 7.63 (tt, *J* = 7.4, 1.4 Hz, 1H, *H4'*), 7.56 (nfom, 1H, *H3'* and *H5'*), 7.47–7.38 [overlapped m, 2H, *H10* and *H8*], 7.36 (nfod, *J*<sub>app</sub> = 6.8 Hz, 2H, *H2'* and *H6'*), 4.79 (br t, *J* = 3.3 Hz, 2H, *C3H2*), 4.04 (br t, *J* = 3.2 Hz, 2H, *C1H2*), 3.09 (s, 3H, CH<sub>3</sub>SO<sub>2</sub>N), 2.72 (s, 3H, NArCH<sub>3</sub>), and 2.20 (s, 3H, C≡CCH<sub>3</sub>).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>): 148.2, 147.7, 145.2, 141.4, 137.5, 135.6, 130.3, 130.2, 130.0, 129.4, 128.7, 128.4, 126.7, 126.5, 126.1, 120.6, 119.5, 96.8, 76.5, 55.8, 54.8, 34.9, 16.8, and 5.0.

**HRMS** (ESI-TOF): Calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [*M*+*H*<sup>+</sup>]<sup>+</sup> requires 427.1475; found 427.1465.

**IR** (neat): 3404, 3059, 3024, 2915, 2852, 2357, 2227, 2045, 2014, 1960, 1721, 1609, 1584, 1496, 1467, 1445, 1412, 1379, 1333, 1286, 1269, 1255, 1079, 1044, 894, 853, 752, 737, 679, 643, 629, 609, 573, 555, 450, 437, and 418 cm<sup>-1</sup>.

**mp**: 262–264 °C (with decomposition).

**Data for 1,4-dihydroacridine 20a, the slower eluting major product:**

**<sup>1</sup>H NMR** (500 MHz, C<sub>6</sub>D<sub>6</sub>): δ 7.10 (m, 2H, *H*2' and *H*6'), 7.05 (dd, *J* = 7.8, 1.6 Hz, 1H, *H*10), 6.977 (ddd, *J* = 7.5, 7.5, 1.6 Hz, 2H, *H*8), 6.975 (nfodd, *J*<sub>app</sub> = 7.4, 7.4 Hz, 2H, *H*3' and *H*5'), 6.89 (tt, *J* = 6.8, 1.3 Hz, 1H, *H*4'), 6.79 (ddd, *J* = 7.4, 7.4, 1.2 Hz, 1H, *H*9), 6.41 (dd, *J* = 8.0, 1.1 Hz, 1H, *H*7), 5.65 (s, 1H, *NH*), 4.85 (dddd, *J* = 13.3, 2.9, 0.9, 0.9 Hz, 1H, MsNC3*H*<sub>a</sub>C3*H*<sub>b</sub>), 4.81 (dd, *J* = 0.6, 0.6 Hz, 1H, *H*11), 4.57 (br dddd, *J* = 13.6, 3.0, 0.9, 0.9 Hz, 1H, MsNC1*H*<sub>a</sub>C1*H*<sub>b</sub>), 4.48 (ddd, *J* = 13.4, 3.1, 1.7 Hz, 1H, MsNC1*H*<sub>a</sub>C1*H*<sub>b</sub>), 4.18 (br d, *J* = 13.5 Hz, 1H, MsNC1*H*<sub>a</sub>C1*H*<sub>b</sub>), 2.14 (s, 3H, CH<sub>3</sub>SO<sub>2</sub>N), 1.94 (s, 3H, NArCH<sub>3</sub>), and 1.69 (s, 3H, C≡CCH<sub>3</sub>).


**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 146.2, 137.8, 137.2, 132.9, 130.7, 129.5, 129.0, 127.7, 127.3, 126.9, 123.1, 122.7, 121.6, 117.8, 117.4, 114.8, 93.9, 75.9, 54.5, 53.5, 45.9, 34.4, 14.8, and 4.7.

**HRMS** (ESI-TOF): Calcd for C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [M+H]<sup>+</sup> requires 429.1631; found 429.1621 (minor ion) and Calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [M-2H]<sup>+</sup> requires 427.1475; found 427.1469 (major ion).

**IR** (neat): 3052, 3033, 3006, 2924, 2873, 2852, 2241, 2222, 2161, 2019, 1715, 1622, 1601, 1560, 1541, 1526, 1492, 1475, 1452, 1445, 1415, 1379, 1355, 1332, 1308, 1294, 1265, 1192, 1156, 1088, 1032, 994, 976, 923, 911, 862, 841, 824, 790, 762, 749, 712, 674, 646, 611, 571, 563, 518, 496, 460, 423, and 415 cm<sup>-1</sup>.

**mp**: 304-306 °C (with decomposition).


### 5-Methyl-2-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3-dihydro-1H-pyrrolo[3,4-a]acridine (**21a**):



The acridine **21a** was synthesized according to General Procedure B (40 mg of amine **20a**). Purification by MPLC (2:1 hexanes:EtOAc) afforded **21a** (30 mg, 77%) as a yellow crystalline solid (characterization data given above).



**5-Methyl-1-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3,6,11-tetrahydro-1H-pyrrolo[2,3-a]acridine (20b)**



Following general procedure A, *N*-(hepta-3,5-diyn-1-yl)-*N*-(penta-1,3-diyn-1-yl)methanesulfonamide (**19b**, 0.020 g, 0.081 mmol, 1 equiv), (*E*)-*N*,1-diphenylmethanimine (**2a**, 0.015 g, 0.088 mmol, 1.1 equiv), and 1,2-dichloroethane (2 mL) were used to prepare the 1,4-dihydroacridine **20b**. Purification of the crude product by MPLC (2:1 hexanes:EtOAc) yielded **20b** (0.023 g, 0.053 mmol, 64%) as a pale yellow amorphous solid.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 7.30 (br d, *J* = 7.5 Hz, 1H, *H*10), 7.16 (ddd, *J* = 9.0, 7.9, 1.5 Hz, 1H, *H*8), 7.10 (br dd, *J* = 7.6, 7.6 Hz, 2H, *PhH*<sub>*m*</sub>), 7.05–7.02 (overlapping m's, 3H, *PhH*<sub>*o*</sub> and *PhH*<sub>*p*</sub>), 6.95 (ddd, *J* = 9.0, 7.5, 1.2 Hz, 1H, *H*9), 6.87 (br d, *J* = 7.9 Hz, 1H, *H*7), 6.36 (s, 1H, *H*11), 6.22 (br s, 1H, *NH*), 4.29 (dd, *J* = 13.0, 7.8 Hz, 1H, *MsNCH*<sub>*a*</sub>*H*<sub>*b*</sub>*CH*<sub>2</sub>), 3.82 (ddd, *J* = 12.9, 12.9, 8.3 Hz, 1H, *MsNCH*<sub>*a*</sub>*H*<sub>*b*</sub>*CH*<sub>2</sub>), 3.21 (ddd, *J* = 16.2, 12.0, 7.8, 1H, *MsNCH*<sub>2</sub>*CH*<sub>*a*</sub>*H*<sub>*b*</sub>), 2.84 (dd, *J* = 16.2, 8.2 Hz, 1H, *MsNCH*<sub>2</sub>*CH*<sub>*a*</sub>*H*<sub>*b*</sub>), 2.72 (s, 3H, *CH*<sub>3</sub>*SO*<sub>2</sub>*N*), 2.40 (s, 3H, *ArCH*<sub>3</sub>), and 2.11 (s, 3H, *C*≡*CCH*<sub>3</sub>).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): 145.5, 139.0, 138.5, 138.3, 130.8, 129.6, 128.3, 127.4, 127.1, 126.2, 123.7, 122.0, 121.3, 119.4, 117.5, 114.3, 93.1, 76.6, 53.5, 42.6, 36.1, 29.8, 14.9, and 4.7.

**HRMS** (ESI-TOF): Calcd for C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [*M*+*H*<sup>+</sup>]<sup>+</sup> requires 429.1631; found 429.1613.

**IR** (neat): 3407, 3057, 3024, 3004, 2955, 2915, 2852, 2342, 2235, 2142, 2000, 1609, 1598, 1577, 1494, 1465, 1434, 1381, 1339, 1328, 1295, 1279, 1252, 1241, 1198, 1154, 1121, 1076, 1045, 1031, 1014, 964, 937, 901, 885, 850, 804, 752, 734, 699, 664, 647, 617, 592, 561, 542, 513, 460, 445, 423, and 405 cm<sup>-1</sup>.

**5-Methyl-1-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3-dihydro-1H-pyrrolo[2,3-a]acridine (21b)**



Following general procedure B, 5-methyl-1-(methylsulfonyl)-11-phenyl-4-(prop-1-yn-1-yl)-2,3,6,11-tetrahydro-1H-pyrrolo[2,3-a]acridine (**20b**, 0.024 g, 0.057 mmol, 1 equiv),  $\text{MnO}_2$  (xs) and  $\text{CHCl}_3$  (10 mL) were used to prepare acridine **21b**. Purification of the crude product yielded acridine **21b** (0.019 g, 0.045 mmol, 80%) as a light green amorphous solid.

**$^1\text{H NMR}$**  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.23 (dd,  $J = 8.7, 0.6$  Hz, 1H,  $H7$ ), 7.88 (br d,  $J = 7.6$  Hz, 1H,  $H2'$  or  $H6'$ ), 7.80 (dd,  $J = 8.8, 0.7$  Hz, 1H,  $H10$ ), 7.69 (ddd,  $J = 8.5, 6.5, 1.4$  Hz, 1H,  $H8$ ), 7.59 (ddd,  $J = 7.5, 7.5, 1.0$  Hz, 1H,  $H3'$  or  $H5'$ ), 7.47 (dddd,  $J = 7.5, 7.5, 1.4, 1.4$  Hz, 1H,  $H4'$ ), 7.39 (ddd,  $J = 8.5, 7.7, 0.9$  Hz, 1H,  $H9$ ), 7.38 (dd,  $J = 7.6, 7.6, 1.4$  Hz, 1H,  $H3'$  or  $H5'$ ), 7.11 (ddd,  $J = 7.8, 1.4, 1.4$  Hz, 1H,  $H2'$  or  $H6'$ ), 3.99 (dd,  $J = 12.0, 7.0$  Hz, 1H,  $\text{MsNCH}_a\text{H}_b\text{CH}_2$ ), 3.70 (ddd,  $J = 11.9, 11.9, 7.9$  Hz, 1H,  $\text{MsNCH}_a\text{H}_b\text{CH}_2$ ), 3.57 (ddd,  $J = 16.2, 11.7, 7.0$  Hz, 1H,  $\text{MsNCH}_2\text{CH}_a\text{H}_b$ ), 3.09 (s, 3H,  $\text{CH}_3\text{SO}_2\text{N}$ ), 3.01 (dd,  $J = 16.2, 7.8$  Hz, 1H,  $\text{MsNCH}_2\text{CH}_a\text{H}_b$ ), 2.21 (overlapping s, 3H,  $\text{ArCH}_3$ ), 2.21 (overlapping s, 3H,  $\text{C}\equiv\text{CCH}_3$ ).


**$^{13}\text{C NMR}$**  (126 MHz,  $\text{CDCl}_3$ ): 148.04, 148.00, 144.7, 140.8, 137.8, 137.0, 133.9, 133.1, 132.1, 130.5, 129.5, 127.7, 127.4, 126.6, 126.5, 126.2, 125.6, 120.9, 119.4, 95.8, 77.1, 52.0, 37.8, 32.0, 17.0, and 5.0.



**HRMS** (ESI-TOF): Calcd for  $\text{C}_{26}\text{H}_{23}\text{N}_2\text{O}_2\text{S}^+$   $[\text{M}+\text{H}^+]^+$  requires 427.1475; found 427.1468.


**IR** (neat): 3055, 3031, 2955, 2917, 2850, 2233, 1730, 1619, 1593, 1548, 1442, 1413, 1353, 1321, 1263, 1150, 1103, 1015, 963, 921, 848, 803, 763, 736, 701, 670, 650, 623, 606, 536, 511, and  $470\text{ cm}^{-1}$ .


**Supporting Information References**


- <sup>1</sup> T. R. Hoye, P. R. Hanson and J. R. Vyvyan, *J. Org. Chem.* 1994, **59**, 4096–4103.
- <sup>2</sup> T. R. Hoye and H. Zhao, *J. Org. Chem.* 2002, **67**, 4014–4016.
- <sup>3</sup> S. Arora, J. Zhang, V. Pogula, T. R. Hoye, *Chem. Sci.* **2019**, *10*, 9069–9076.
- <sup>4</sup> J. Chen, V. Palani, T. R. Hoye, *J. Am. Chem. Soc.* **2016**, *138*, 4318–4321.
- <sup>5</sup> T. C. Malig, D. Yu, J. E. Hein, *J. Am. Chem. Soc.* **2018**, *140*, 9167–9173,
- <sup>6</sup> Madhuprasad, N. Swathi, J. R. Manjunatha, U. K. Das, A. N. Shetty, D. R. Trivedi, *New J. Chem.* **2014**, *38*, 1484.
- <sup>7</sup> J. R. Lawson, L. C. Wilkins, R. L. Melen, *Chem. Eur. J.* **2017**, *23*, 10997–11000.
- <sup>8</sup> X. Yang, L. Zhao, T. Fox, Z. X. Wang, H. Berke, *Angew. Chem. Int. Ed.* **2010**, *49*, 2058–2062.
- <sup>9</sup> M. Vayer, S. P. Morcillo, J. Dupont, V. Gandon, C. Bour, *Angew. Chem. Int. Ed.* **2018**, *57*, 3228–3232
- <sup>10</sup> C. W. Chen, M. C. Tseng, S. K. Hsiao, W. H. Chen, Y. H. Chu, *Org. Biomol. Chem.* **2011**, *9*, 4188–4193.
- <sup>11</sup> N. M. O’Boyle, J. K. Pollock, M. Carr, A. J. S. Knox, S. M. Nathwani, S. Wang, L. Caboni, D. M. Zisterer, M. J. Meegan, *J. Med. Chem.* **2014**, *57*, 9370–9382.
- <sup>12</sup> N. Chen, X. J. Dai, H. Wang, C. J. Li, *Angew. Chem. Int. Ed.* **2017**, *56*, 6260–6263.
- <sup>13</sup> Y. Wu, G. Zhou, Q. Meng, X. Tang, G. Liu, H. Yin, J. Zhao, F. Yang, Z. Yu, Y. Luo, *J. Org. Chem.* **2018**, *83*, 13051–13062.






































































193.6  
158.5  
153.0  
149.0  
143.0  
142.5  
141.1  
137.6  
137.5  
136.9  
133.7  
128.7  
128.6  
128.1  
127.7  
125.3  
124.2  
122.2  
119.1  
115.1  
114.4  
107.8  
106.6

77.4  $\text{CDCl}_3$   
77.2  $\text{CDCl}_3$   
76.9  $\text{CDCl}_3$


56.5  
56.2  
55.3


43.8


18.2


3.2  
0.1



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10  
f1 (ppm)



















































7.26 CDCl<sub>3</sub>

7.19

7.17

7.10

7.10

6.97

6.96

6.76

6.76

6.75

6.74

6.72

5.36

5.36

3.92

3.86

3.79

3.69

-2.42

0.45

-0.00

2.09

1.81

0.92

3.51

0.88

1.00

2.97

2.79


2.92


2.83


2.97


9.40



8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5  
f1 (ppm)










































































148.04  
148.00  
144.65  
140.77  
137.81  
137.01  
133.13  
132.11  
130.49  
129.52  
127.71  
127.37  
126.62  
126.48  
126.21  
125.94  
120.94  
119.38

95.84

77.41 CDCl<sub>3</sub>  
77.16 CDCl<sub>3</sub>  
77.12  
76.91 CDCl<sub>3</sub>

52.02

37.76

32.00

17.03

4.95

0.14

